Building the Evidence System that could have caught it earlier
Sep 17
1 min read
What if the evidence was already telling you the program was at risk?
An uncertain endpoint. A subgroup signal carrying too much weight. A clinical trial population that doesn't reflect real-world disease burden. Unanswered questions about RWE or payer value.
In this brief, Rubix LS examines six evidence risks that can shape the next development, partnership, or investment decision, with a framework for knowing when to advance, redirect, or stop.
Because the most expensive uncertainty is the kind you carry forward without testing.
